U.K. DRUG FOR ABUSE TESTING DEVICES MARKET ANALYSIS

Drugs for abuse testing devices aids in detecting presence of drug in the human body. Drugs for abuse testing devices comprises kits and devices. Drugs for abuse testing is basically performed using urine, hair, and saliva samples. Moreover, it also include blood and nail samples for testing. Urine is the specimen of choice because it contains secreted metabolites, which can be used to detect the presence of illicit drugs such as cocaine, heroin, diazepam, methamphetamine, marijuana, lorazepam, anabolic steroids. The equipment used in drug for abuse testing include immunoassay analyzers, chromatography instruments, breath analyzers, oral fluid testing devices, urine testing devices, and consumables. The key end users in drug for abuse testing market involve hospitals, laboratories, home users.

The U.K. drug for abuse testing devices market is estimated to be valued at US$ 275.7 million in 2020, and is expected to exhibit a CAGR of 5.0% during the forecast period (2020-2027).

Figure 1. U.K. Drug for Abuse Testing Devices Market Share (%), in Terms of Value, By Product Type, 2020

To learn more about this report, request sample copy

The rising incidence of drunk and drive cases and drug addiction are expected to drive the market growth during the forecast period.

The increasing incidence of drunk and drive cases, and drug addiction is expected to drive the U.K. drug for abuse testing devices market growth over the forecast period. For instance, according to the National Health Service U.K. report, in 2017, there were around 15,074 hospital admissions with a primary diagnosis of poisoning by illicit drugs in England.

Figure 2. U.K. Drug for Abuse Testing Devices Market Share (%), by End User, 2020

To learn more about this report, request sample copy

Increasing product launch and approval is expected to drive the U.K. for drug abuse tesing devices market growth during the forecast period.

Increasing product launches and approvals expected to boost the market growth during the forecast period. For instance, In September 2018, Securetec Detektions-Systeme AG launched new WipeAlyser, a mobile analyzer for use with the proven DrugWipe drug rapid test. Furthermore, in 2016, Securetec Detektions-Systeme AG launched updated version of DrugWipe 5 S. The company shortened the test duration to 5 minutes while increasing the sensitivity of the DrugWipe 5 S saliva test for cannabis.

U.K. Drug for Abuse Testing Devices Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries, across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of Coronavirus (COVID-19) has resulted in over 153 million infected individuals worldwide, as of May 4^, 2021.

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.

Furthermore, players operating in the U.K. drug for abuse testing devices market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing of testing devices due to irregularities in transportation.

U.K. Drug for Abuse Testing Devices Market: Restraint

The major factors that are expected to hinder growth of the U.K. drug for abuse testing devices market include availability of low cost alcohol Breathalyzer and drug testing devices manufactured by local players and inaccurate & false results by breath analyzers and testing devices.

Key Players

Major players operating in the U.K. drug for abuse testing devices market include Abbott Laboratories, Thermo Fisher Scientific, Inc, Drägerwerk AG & Co. KGaA, Laboratory Corporation of America Holdings, Quest Diagnostics, Alfa Scientific Designs, Inc, Lifeloc Technologies Inc, Lion Laboratories Limited, OraSure Technologies, Inc, Omega Laboratories, Inc., Shimadzu Corporation, Siemens Healthineers, F. Hoffmann-La Roche AG, Premier Biotech, Inc, Psychemedics Corporation, Innovative Testing Solutions, Biopanda Reagents Ltd, Alpha Laboratories, Matrix Diagnostics, Atlas Medical, Rapid Labs Limited, and Randox Laboratories Ltd.